- $5.08m
- $3.29m
- $6.16m
Brief: AMA Issues CPT Code For bioAffinity Technologies' Cypath Lung Test
Brief: BioAffinity Technologies Reports First Quarter 2023 Financial Results
Brief: Bioaffinity Technologies Names Michael Dougherty As Chief Financial Officer
Brief: Bioaffinity Technologies Reports Q4 Results
Brief: bioAffinity Appoints Julie Overton As Director Of Corporate Communications
Brief: Bioaffinity Technologies Announces Publication Of Results Of Clinical Trial In Peer-Reviewed Journal Respiratory Research
Brief: bioAffinity Technologies Expands Diagnostic Division With Promotions And New Hires To Strengthen Clinical Bench
Brief: Bioaffinity Technologies Reports Q3 Results, Provides Business Update
Brief: Bioaffinity Technologies Announces Sheila Habib And David Hill Join The Company's Scientific And Medical Advisory Board
Brief: BioAffinity Technologies Announces Award Of Therapeutic Patents In China, Mexico And Australia
Brief: bioAffinity Technologies Receives Additional $7.7M From Exercise Of Warrants, Total Capital From Public Offering Increases To Approximately $15.6M
Brief: bioAffinity Technologies Publishes Peer-Reviewed Results Of High-Throughput Flow Cytometry Use For Evaluating Lung Health In PLOS ONE
BioAffinity Technologies extends gains after stellar Nasdaq debut
U.S. STOCKS ON THE MOVE-Pfizer, Nvidia, Boeing, SAIC, BioAffinity, Polestar
Diagnostic firm BioAffinity's shares more than double on Nasdaq debut
Brief: bioAffinity Prices IPO At $6.125 Per Unit